(CercleFinance.com) – Bayer and Asklepios BioPharmaceutical (AskBio), a wholly owned and independently operated company as a subsidiary of Bayer, presented results from the 18-month Phase Ib clinical trial for AB- 1005, an investigational gene therapy for the treatment of patients with Parkinson’s disease (PD).
The data was presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.
AB-1005 was well tolerated with no serious side effects attributed in all 11 patients at 18 months, meeting the primary endpoint.
Based on the presented safety and efficacy results, a Phase II trial (REGENERATE PD) has been developed and is expected to begin recruiting in the United States, European Union, and United Kingdom later this year .
“These initial results are encouraging and demonstrate that AB-1005 is well tolerated in this study in patients with mild to moderate Parkinson’s disease,” said Krystof Bankiewicz, MD, PhD, scientific chair, Parkinson’s Disease and MSA, AskBio.
‘Additionally, they highlight areas for potential future exploration in our upcoming Phase II REGENERATE PD study, which will more closely examine the potential effectiveness of AB-1005 in the treatment of Parkinson’s disease.’
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
